Aim: This study aimed to investigate the effect of non-synonymous SNPs (nsSNPs) of the Glucagon-like peptide-1 Receptor (GLP-1R) gene in protein function and structure using different computational software. Introduction: The GLP1R gene provides the necessary instruction for the synthesis of the insulin hormones which is needed for glucose catabolism. Polymorphisms in this gene are associated with diabetes. The protein is an important drug target for the treatment of type-2 diabetes and stroke. Material and Methods: Different nsSNPs and protein-related sequences were obtained from NCBI and ExPASY database. Gene associations and interactions were predicted using GeneMANIA software. Deleterious and damaging effects of nsSNPs were analyzed using SIFT, Provean, and Polyphen-2. The association of the nsSNPs with the disease was predicted using SNPs & GO software. Protein stability was investigated using I-Mutant and MUpro software. The structural and functional impact of point mutations was predicted using Project Hope software. Project Hope analyzes the mutations according to their size, charge, hydrophobicity, and conservancy. Results: The GLP1R gene was found to have an association with 20 other different genes. Among the most important ones is the GCG (glucagon) gene which is also a trans membrane protein. Overall 7229 variants were seen, and the missense variants or nsSNPs (146) were selected for further analysis. The total number of nsSNPs obtained in this study was 146. After being subjected to SIFT software (27 Deleterious and 119 Tolerated) were predicted. Analysis with Provean showed that (20 deleterious and 7 neutral). Analysis using Polyphen-2 revealed 17 probably damaging, 2 possibly damaging and 1 benign nsSNPs. Using two additional software SNPs & GO and PHD-SNPs showed that 14 and 17 nsSNPs had a disease effect, respectively. Project Hope software predicts the effect of the 14 nsSNPs on the protein function due to differences in charge, size, hydrophobicity, and conservancy between the wild and mutant types. Conclusion: In this study, the 14 nsSNPs which were highly affected the protein function. This protein is providing the necessary instruction for the synthesis of the insulin hormones which is needed for glucose catabolism. Polymorphisms in this gene are associated with diabetes and also affect the treatment of diabetic patients due to the fact that the protein acts as an important drug target.
References
[1]
Cerf, M.E. (2013) Beta Cell Dysfunction and Insulin Resistance. Frontiers in Endocrinology, 4, Article 37. https://doi.org/10.3389/fendo.2013.00037
[2]
Stumvoll, M., Goldstein, B.J. and van Haeften, T.W. (2005) Type 2 Diabetes: Principles of Pathogenesis and Therapy. Lancet, 365, 1333-1346.
https://doi.org/10.1016/S0140-6736(05)61032-X
[3]
DeFronzo, R.A. (2004) Pathogenesis of Type 2 Diabetes Mellitus. Medical Clinics of North America, 88, 787-835. https://doi.org/10.1016/j.mcna.2004.04.013
[4]
Røder, M.E. (2017) Hyperproinsulinemia in Obesity and in Type 2 Diabetes and Its Relation to Cardiovascular Disease. Expert Review of Endocrinology & Metabolism, 12, 227-239. https://doi.org/10.1080/17446651.2017.1331735
[5]
Lovic, D., Piperidou, A., Zografou, I., Grassos, H., Pittaras, A. and Manolis, A. (2020) The Growing Epidemic of Diabetes Mellitus. Current Vascular Pharmacology, 18, 104-109. https://doi.org/10.2174/1570161117666190405165911
[6]
Chadha, M., Jain, S.M., Chawla, R., Dharmalingam, M., Chaudhury, T., Talwalkar, P.G., Tripathi, S., Singh, S.K., Gutch, M. and Dasgupta, A. (2023) Evolution of Guideline Recommendations on Insulin Therapy in Type 2 Diabetes Mellitus over the Last Two Decades: A Narrative Review. Current Diabetes Reviews, 19, 84-94.
https://doi.org/10.2174/1573399819666230116150205
[7]
Nguyen, K.T. and Korner, J. (2014) The Sum of Many Parts: Potential Mechanisms for Improvement in Glucose Homeostasis after Bariatric Surgery. Current Diabetes Reports, 14, Article No. 481. https://doi.org/10.1007/s11892-014-0481-5
[8]
Baggio, L.L. and Drucker, D.J. (2007) Biology of Incretins: GLP-1 and GIP. Gastroenterology, 132, 2131-2157. https://doi.org/10.1053/j.gastro.2007.03.054
[9]
Tokuyama, Y., Matsui, K., Egashira, T., Nozaki, O., Ishizuka, T., and Kanatsuka, A. (2004) Five Missense Mutations in Glucagon-Like Peptide 1 Receptor Gene in Japanese Population. Diabetes Research and Clinical Practice, 66, 63-69.
https://doi.org/10.1016/j.diabres.2004.02.004
[10]
Aslam, M. and Ladilov, Y. (2022) Emerging Role of cAMP/AMPK Signaling. Cells, 11, Article No. 308. https://doi.org/10.3390/cells11020308
[11]
Kimple, M.E., Neuman, J.C., Linnemann, A.K. and Casey, P.J. (2014) Inhibitory G Proteins and Their Receptors: Emerging Therapeutic Targets for Obesity and Diabetes. Experimental & Molecular Medicine, 46, e102.
https://doi.org/10.1038/emm.2014.40
[12]
Tovey, S.C., Dedos, S.G., Rahman, T., Taylor, E.J., Pantazaka, E. and Taylor, C.W. (2010) Regulation of Inositol 1,4,5-Trisphosphate Receptors by cAMP Independent of cAMP-Dependent Protein Kinase. Journal of Biological Chemistry, 285, 12979-12989.
https://doi.org/10.1074/jbc.M109.096016
[13]
Yang, H. and Yang, L. (2016) Targeting cAMP/PKA Pathway for Glycemic Control and Type 2 Diabetes Therapy. Journal of Molecular Endocrinology, 57, R93-R108.
https://doi.org/10.1530/JME-15-0316
[14]
Franz, M., Rodriguez, H., Lopes, C., Zuberi, K., Montojo, J., Bader, G.D. and Morris, Q. (2018) GeneMANIA Update 2018. Nucleic Acids Research, 46, W60-W64.
https://doi.org/10.1093/nar/gky311
[15]
Kumar, P., Henikoff, S. and Ng, P.C. (2009) Predicting the Effects of Coding Non-Synonymous Variants on Protein Function Using the SIFT Algorithm. Nature Protocols, 4, 1073-1081. https://doi.org/10.1038/nprot.2009.86
[16]
Hassan, M.S., Shaalan, A., Dessouky, M., Abdelnaiem, A.E. and ElHefnawi, M.A. (2019) A Review Study: Computational Techniques for Expecting the Impact of Non-Synonymous Single Nucleotide Variants in Human Diseases. Gene, 680, 20-33.
https://doi.org/10.1016/j.gene.2018.09.028
[17]
Adzhubei, I.A., Schmidt, S., Peshkin, L., Ramensky, V.E., Gerasimova, A., Bork, P., Kondrashov, A.S. and Sunyaev, S.R. (2010) A Method and Server for Predicting Damaging Missense Mutations. Nature Methods, 7, Article No. 248.
https://doi.org/10.1038/nmeth0410-248
[18]
Adzhubei, I., Jordan, D.M. and Sunyaev, S.R. (2013) Predicting Functional Effect of Human Missense Mutations Using PolyPhen-2. Current Protocols in Human Genetics, 76, 7-20. https://doi.org/10.1002/0471142905.hg0720s76
[19]
Calabrese, R., Capriotti, E., Fariselli, P., Martelli, P.L. and Casadio, R. (2009) Functional Annotations Improve the Predictive Score of Human Disease-Related Mutations in Proteins. Human Mutation, 30, 1237-1244.
https://doi.org/10.1002/humu.21047
[20]
Capriotti, E., Calabrese, R. and Casadio, R. (2006) Predicting the Insurgence of Human Genetic Diseases Associated to Single Point Protein Mutations with Support Vector Machines and Evolutionary Information. Bioinformatics, 22, 2729-2734.
https://doi.org/10.1093/bioinformatics/btl423
[21]
Cheng, J., Randall, A. and Baldi, P. (2006) Prediction of Protein Stability Changes for Single-Site Mutations Using Support Vector Machines. Proteins: Structure, Function, and Bioinformatics, 62, 1125-1132. https://doi.org/10.1002/prot.20810
[22]
Venselaar, H., teBeek, T.A., Kuipers, R.K., Hekkelman, M.L. and Vriend, G. (2010) Protein Structure Analysis of Mutations Causing Inheritable Diseases. An E-Science Approach with Life Scientist Friendly Interfaces. BMC Bioinformatics, 11, Article No. 548. https://doi.org/10.1186/1471-2105-11-548
[23]
Stefl, S., Nishi, H., Petukh, M., Panchenko, A.R. and Alexov, E. (2013) Molecular Mechanisms of Disease-Causing Missense Mutations. Journal of Molecular Biology, 425, 3919-3936. https://doi.org/10.1016/j.jmb.2013.07.014
[24]
Nzabonimpa, G.S., Rasmussen, H.B., Brunak, S. and Taboureau, O. (2016) Investigating the Impact of Missense Mutations in hCES1 by in Silico Structure-Based Approaches. Drug Metabolism and Personalized Therapy, 31, 97-106.
https://doi.org/10.1515/dmpt-2015-0034
[25]
Müller, T.D., Finan, B., Bloom, S.R., D'Alessio, D., Drucker, D.J., Flatt, P.R., Fritsche, A., Gribble, F., Grill, H.J., Habener, J.F., Holst, J.J., Langhans, W., Meier, J.J., Nauck, M.A., Perez-Tilve, D., Pocai, A., Reimann, F., Sandoval, D.A., Schwartz, T.W., et al. (2019) Glucagon-Like Peptide 1 (GLP-1). Molecular Metabolism, 30, 72-130.
https://doi.org/10.1016/j.molmet.2019.09.010
[26]
Boer, G.A. and Holst, J.J. (2020) Incretin Hormones and Type 2 Diabetes—Mechanistic Insights and Therapeutic Approaches. Biology, 9, Article No. 473.
https://doi.org/10.3390/biology9120473
[27]
Anderson, S.L., Trujillo, J.M., McDermott, M., and Saseen, J.J. (2012) Determining Predictors of Response to Exenatide in Type 2 Diabetes. Journal of the American Pharmacists Association, 52, 466-471. https://doi.org/10.1331/JAPhA.2012.10217
[28]
Sathananthan, A., Man, C.D., Micheletto, F., Zinsmeister, A.R., Camilleri, M., Giesler, P.D., et al. (2010) Common Genetic Variation in GLP1R and Insulin Secretion in Response to Exogenous GLP-1 in Nondiabetic Subjects: A Pilot Study. Diabetes Care, 33, 2074-2076. https://doi.org/10.2337/dc10-0200
[29]
Li, W., Li, P., Li, R., Yu, Z., Sun, X., Ji, G., Yang, X., Zhu, L. and Zhu, S. (2020) GLP1R Single-Nucleotide Polymorphisms rs3765467 and rs10305492 Affect β Cell Insulin Secretory Capacity and Apoptosis through GLP-1. DNA and Cell Biology, 39, 1700-1710. https://doi.org/10.1089/dna.2020.5424
[30]
Villalba, A., Rodriguez-Fernandez, S., Perna-Barrull, D., Ampudia, R.M., Gomez-Muñoz, L., Pujol-Autonell, I., Aguilera, E., Coma, M., Cano-Sarabia, M., Vázquez, F. and Verdaguer, J. (2020) Repurposed Analog of GLP-1 Ameliorates Hyperglycemia in Type 1 Diabetic Mice through Pancreatic Cell Reprogramming. Frontiers in Endocrinology, 11, Article 258. https://doi.org/10.3389/fendo.2020.00258
